Based on these alterations and the previous studies showing the efficacy of bromodomain and extraterminal motif (BET) inhibitors for primary GBMs, the authors tested BET inhibitors on IDH1-mutant glioma cells. The gene discussed is IDH1; the disease is central nervous system cancer.